GoodRx reports that in 2025, novel drug and biosimilar approvals lag slightly behind last year, while first generic approvals ...

“Biosimilars are demonstrating their safety and effectiveness, with more than 2.7 billion days of patient therapy with no ...

A growing disconnect remains between what generics are approved and what are actually accessible, GoodRx said.

Gen Z is most likely to prefer brand-name drugs—despite being an average 79% more expensive than their generic counterparts—according to a Tebra survey published in January 2025.

An authorized generic is different from a generic drug, according to the FDA, because it’s the “exact same drug product” as a branded drug, just without the brand name on the label. A ...